Altria Group (MO) posted stronger-than-expected Q4 revenue, driven by its core tobacco brands and oral nicotine products, but saw its shares fall as profit margins contracted sharply. The company is betting on a national rollout of its ON! Plus pouches and manufacturing upgrades to fuel its smoke-free future.
The Federal Reserve's decision to hold interest rates steady signals a strategic pause, not an end to its easing cycle. We break down the immediate and future impacts on everything from credit cards to the housing market.
Parker-Hannifin (PH) exceeded Q4 2025 revenue and profit expectations, driven by margin expansion and its recent Filtration Group purchase. The industrial giant has raised its full-year guidance, citing strength in aerospace and a recovering industrial landscape.
Nasdaq Inc. reported stronger-than-expected fourth-quarter results, fueled by surging revenue from its technology solutions division and strategic AI initiatives, even as the company navigates a tighter margin environment.
Trane Technologies (TT) surpassed Wall Street expectations for Q4 2025, driven by surging demand in commercial HVAC systems and data center infrastructure. The company reported revenue of $5.14B, up 5.5% year-over-year, with earnings per share of $2.86. Management expressed confidence for 2026, citing a record order backlog.
The business services sector has outperformed, riding a wave of corporate demand for efficiency. But with economic sensitivity looming, we analyze two companies with robust models and one where caution may be warranted.
The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.
The financial services sector, a traditional engine of economic growth, is underperforming the S&P 500 amid economic uncertainty. We examine three specific stocks—Invesco, Enova International, and Sixth Street Specialty Lending—that investors may want to approach with heightened caution.
Secretary-General António Guterres warns the United Nations could exhaust its regular budget cash by July, citing chronic non-payment of dues by member states and a "Kafkaesque" financial cycle that threatens its core operations.
Moody's Corporation bolsters its risk analytics arsenal with strategic acquisitions of Numerated Growth Technologies and CAPE Analytics, positioning itself at the center of a private credit market under the regulatory microscope.
TAL Education Group's stock soared following robust Q3 FY2026 results and a new share repurchase program, marking a potential inflection point for the Chinese tutoring giant navigating a post-regulatory landscape. Analysts debate if the rally signals a lasting recovery or a temporary reprieve.
Footwear giant Deckers Brands posted quarterly revenue and profit that handily beat Wall Street estimates, driven by surging global demand for its HOKA and UGG labels. The company raised its full-year outlook, citing robust direct-to-consumer growth and international momentum.
International Flavors & Fragrances (IFF) shares have lagged the broader market, raising questions about its turnaround strategy and long-term value proposition for investors.
With its share price up nearly 40% in a month, Bannerman Energy (ASX:BMN) is drawing intense investor scrutiny ahead of its December quarter report and investor webinar. Analysts weigh whether the uranium developer's rally has outpaced fundamentals.
Atlassian confronts a mounting identity theft campaign targeting its systems while rival Anthropic launches a competing AI collaboration tool, adding pressure to a stock already down over 50% in the past year.
CNBC's Jim Cramer suggests Intel shares could surge significantly, as the chipmaker's strategic overhaul and analyst upgrades fuel investor optimism amid a 140% yearly gain.
Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
The U.S. Federal Trade Commission has issued warnings to 42 prominent law firms, suggesting their diversity, equity, and inclusion hiring initiatives could violate antitrust laws by potentially restricting competition for talent.
